• Barton, W.A., Tzvetkova, D., and Nikolov, D.B. 2005. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure 13: 825832.
  • Brantley, D.M., Cheng, N., Thompson, E.J., Lin, Q., Brekken, R.A., Thorpe, P.E., Muraoka, R.S., Cerretti, D.P., Pozzi, A., and Jackson, D., et al. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 70117026.
  • Davis, S., Gale, N., Aldrich, T., Maisonpierre, P., Lhotak, V., Pawson, T., Goldfarb, M., and Yancopoulos, G. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266: 816819.
  • Day, B., To, C., Himanen, J.-P., Smith, F.M., Nikolov, D.B., Boyd, A.W., and Lackmann, M. 2005. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J. Biol. Chem. 280: 2652626532.
  • Dodelet, V.C. and Pasquale, E.B. 2000. Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis. Oncogene 19: 56145619.
  • Drescher, U., Kremoser, C., Handwerker, C., Loschinger, J., Noda, M., and Bonhoeffer, F. 1995. In vitro guidance of retinal ganglion cell axons by RAGS, a 25 kDa tectal protein related to ligands for Eph receptor tyrosine kinases. Cell 82: 359370.
  • Eph Nomenclature Committee 1997. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90: 403404.
  • Flanagan, J.G. and Vanderhaeghen, P. 1998. The ephrins and Eph receptors in neural development. Annu. Rev. Neurosci. 21: 309345.
  • Hafner, C., Schmitz, G., Meyer, S., Bataille, F., Hau, P., Langmann, T., Dietmaier, W., Landthaler, M., and Vogt, T. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50: 490499.
  • Himanen, J.P. and Nikolov, D.B. 2003. Eph signaling: A structural view. Trends Neurosci. 26: 4651.
  • Himanen, J.P., Chumley, M.J., Lackmann, M., Li, C., Barton, W.A., Jeffrey, P.D., Vearing, C., Geleick, D., Feldheim, D.A., and Boyd, A.W., et al. 2004. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 7: 501509.
  • Lackmann, M., Mann, R.J., Kravets, L., Smith, F.M., Bucci, T.A., Maxwell, K.F., Howlett, G.J., Olsson, J.E., Vanden Bos, T., and Cerretti, D.P., et al. 1997. Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J. Biol. Chem. 272: 1652116530.
  • Lackmann, M., Oates, A.C., Dottori, M., Smith, F.M., Do, C., Power, M., Kravets, L., and Boyd, A.W. 1998. Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J. Biol. Chem. 273: 2022820237.
  • Mammen, M., Choi, S.K., and Whitesides, G.M. 1998. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. Engl. 37: 27552794.
  • Murai, K.K. and Pasquale, E.B. 2003. ‘Eph’ective signaling: Forward, reverse and crosstalk. J. Cell Sci. 116: 28232832.
  • Ogawa, K., Pasqualini, R., Lindberg, R.A., Kain, R., Freeman, A.L., and Pasquale, E.B. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 60436052.
  • Pasquale, E.B. 2005. EPH receptor signaling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6: 462475.
  • Poliakov, A., Cotrina, M., and Wilkinson, D.G. 2004. Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell 7: 465480.
  • Stein, E., Lane, A.A., Cerretti, D.P., Schoecklmann, H.O., Schroff, A.D., Van Etten, R.L., and Daniel, T.O. 1998. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes & Dev. 12: 667678.
  • Takahashi, T., Takahashi, K., Gerety, S., Wang, H., Anderson, D.J., and Daniel, T.O. 2001. Temporally compartmentalized expression of ephrin-B2 during renal glomerular development. J. Am. Soc. Nephrol. 12: 26732682.
  • Tang, X.X., Evans, A.E., Zhao, H.Q., Cnaan, A., London, W., Cohn, S.L., Cheung, N.K.V., Brodeur, G.M., and Ikegaki, N. 1999. High level expression of EPHB6, EFNB2 and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastoma. Clin. Cancer Res. 5: 14911496.
  • Vogt, T., Stolz, W., Welsh, J., Jung, B., Kerbel, R.S., Kobayashi, H., Landthaler, M., and McClelland, M. 1998. Overexpression of Lerk-5/Eplg5 messenger RNA: A novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin. Cancer Res. 4: 791797.